Discrepant alterations in main candidate genes among multiple primary melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

(2013) Jean-François Emile et al.   BMC CANCER

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

(2013) L Heinzerling et al.   BRITISH JOURNAL OF CANCER

Multiple primary melanomas: do they look the same?

(2013) E. Moscarella et al.   BRITISH JOURNAL OF DERMATOLOGY

Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance

(2013) A. L. Pritchard et al.   CLINICAL CANCER RESEARCH

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

(2013) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

(2013) Paolo A Ascierto et al.   Journal of Translational Medicine

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

(2013) Maria Colombino et al.   Journal of Translational Medicine

Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma

(2013) M. S. Carlino et al.   MOLECULAR CANCER THERAPEUTICS

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Single versus multiple primary melanomas

(2012) Charlotte Hwa et al.   CANCER

BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

(2012) Maria Colombino et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma

(2012) Wesley O. Greaves et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy

(2012) M Colombino et al.   Cell Death & Disease

Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas

(2011) Rajmohan Murali et al.   ANNALS OF SURGICAL ONCOLOGY

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

(2011) J Lin et al.   BRITISH JOURNAL OF CANCER

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

(2011) Y. Kong et al.   CLINICAL CANCER RESEARCH

The role of mitogen- and stress-activated protein kinase pathways in melanoma

(2011) Pablo Lopez-Bergami   Pigment Cell & Melanoma Research

Multiple primary melanoma: the impact of atypical naevi and follow up

(2010) V. De Giorgi et al.   BRITISH JOURNAL OF DERMATOLOGY

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

(2010) J.-H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study

(2010) Andreas Gast et al.   GENES CHROMOSOMES & CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The MAPK pathway in melanoma

(2009) Leslie A Fecher et al.   CURRENT OPINION IN ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Main roads to melanoma

(2009) Giuseppe Palmieri et al.   Journal of Translational Medicine

Cutaneous melanoma in the era of molecular profiling

(2009) John F Thompson et al.   LANCET

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma

(2009) Viktória Lázár et al.   MODERN PATHOLOGY

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS